Algert Global LLC Buys 51,110 Shares of Tyra Biosciences, Inc. $TYRA

Key Points

• Algert Global increased its Tyra Biosciences stake by 27.2% in the second quarter, purchasing 51,110 additional shares for a total of 239,120 shares valued at approximately $7.6 million.
• Institutional ownership remains high at 84.14%, with several hedge funds increasing positions or initiating new stakes during the first and second quarters.
• Analysts maintain a consensus “Moderate Buy” rating with an average price target of $46.90, while Tyra recently reported a quarterly loss of $0.69 per share, missing estimates by $0.04.

Algert Global LLC increased its stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 27.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 239,120 shares of the company's stock after buying an additional 51,110 shares during the period. Algert Global LLC owned about 0.40% of Tyra Biosciences worth $7,637,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TYRA. Millennium Management LLC raised its holdings in shares of Tyra Biosciences by 28.2% in the 1st quarter. Millennium Management LLC now owns 404,165 shares of the company's stock worth $3,759,000 after purchasing an additional 89,024 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Tyra Biosciences by 21.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company's stock worth $725,000 after acquiring an additional 13,896 shares during the period. Woodline Partners LP purchased a new stake in Tyra Biosciences in the 1st quarter worth about $931,000. Jane Street Group LLC bought a new stake in Tyra Biosciences in the 1st quarter valued at about $324,000. Finally, Geode Capital Management LLC raised its stake in Tyra Biosciences by 9.8% in the 2nd quarter. Geode Capital Management LLC now owns 567,126 shares of the company's stock valued at $5,428,000 after acquiring an additional 50,836 shares during the period. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TYRA has been the subject of several recent research reports. Wolfe Research began coverage on shares of Tyra Biosciences in a research note on Tuesday, May 19th. They issued a "peer perform" rating for the company. Bank of America raised their price objective on shares of Tyra Biosciences from $37.00 to $42.00 and gave the stock a "buy" rating in a report on Wednesday, June 10th. JonesTrading began coverage on shares of Tyra Biosciences in a report on Wednesday, June 17th. They set a "buy" rating and a $56.00 target price on the stock. Jefferies Financial Group restated a "buy" rating and set a $42.00 target price on shares of Tyra Biosciences in a research report on Wednesday, August 5th. Finally, HC Wainwright reiterated a "buy" rating and issued a $45.00 price target on shares of Tyra Biosciences in a research report on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $46.90.

Tyra Biosciences Stock Performance

Shares of NASDAQ:TYRA opened at $26.22 on Thursday. The firm has a market capitalization of $1.56 billion, a PE ratio of -10.93 and a beta of 0.77. Tyra Biosciences, Inc. has a 52-week low of $11.70 and a 52-week high of $40.65. The firm has a fifty day moving average of $29.62 and a 200 day moving average of $32.25.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.04). On average, sell-side analysts forecast that Tyra Biosciences, Inc. will post -2.74 EPS for the current fiscal year.

About Tyra Biosciences

Tyra Biosciences NASDAQ: TYRA is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company's pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.

Want to see what other hedge funds are holding TYRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source